 |
The Journal of Neuroscience, April 27, 2005, 25(17):4319-4329; doi:10.1523/JNEUROSCI.5200-04.2005
Previous Article | Next Article 
Cellular/Molecular
Activation of Protease-Activated Receptor-1 Triggers Astrogliosis after Brain Injury
Olivier Nicole,1,3
Anna Goldshmidt,1
Cecily E. Hamill,1
Scott D. Sorensen,1
Aristide Sastre,1
Polina Lyuboslavsky,1
John R. Hepler,1
Robert J. McKeon,2 and
Stephen F. Traynelis1
Departments of 1Pharmacology and 2Cell Biology, Emory University School of Medicine, Atlanta, Georgia 30322, and 3Université de Caen, Unité Mixte de Recherche-Centre National de la Recherche Scientifique 6185, 14074 Caen Cedex, France
We have studied the involvement of the thrombin receptor [protease-activated receptor-1 (PAR-1)] in astrogliosis, because extravasation of PAR-1 activators, such as thrombin, into brain parenchyma can occur after blood-brain barrier breakdown in a number of CNS disorders. PAR1-/- animals show a reduced astrocytic response to cortical stab wound, suggesting that PAR-1 activation plays a key role in astrogliosis associated with glial scar formation after brain injury. This interpretation is supported by the finding that the selective activation of PAR-1 in vivo induces astrogliosis. The mechanisms by which PAR-1 stimulates glial proliferation appear to be related to the ability of PAR-1 receptor signaling to induce sustained extracellular receptor kinase (ERK) activation. In contrast to the transient activation of ERK by cytokines and growth factors, PAR-1 stimulation induces a sustained ERK activation through its coupling to multiple G-protein-linked signaling pathways, including Rho kinase. This sustained ERK activation appears to regulate astrocytic cyclin D1 levels and astrocyte proliferation in vitro and in vivo. We propose that this PAR-1-mediated mechanism underlying astrocyte proliferation will operate whenever there is sufficient injury-induced blood-brain barrier breakdown to allow extravasation of PAR-1 activators.
Key words: protease receptor; thrombin; astrogliosis; trauma; MAP kinase; G-protein
Received July 30, 2004;
revised March 18, 2005;
accepted March 18, 2005.
This article has been cited by other articles:

|
 |

|
 |
 
S. Citro, S. Malik, E. A. Oestreich, J. Radeff-Huang, G. G. Kelley, A. V. Smrcka, and J. H. Brown
Phospholipase C{varepsilon} is a nexus for Rho and Rap-mediated G protein-coupled receptor-induced astrocyte proliferation
PNAS,
September 25, 2007;
104(39):
15543 - 15548.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. E. Hamill, W. M. Caudle, J. R. Richardson, H. Yuan, K. D. Pennell, J. G. Greene, G. W. Miller, and S. F. Traynelis
Exacerbation of Dopaminergic Terminal Damage in a Mouse Model of Parkinson's Disease by the G-Protein-Coupled Receptor Protease-Activated Receptor 1
Mol. Pharmacol.,
September 1, 2007;
72(3):
653 - 664.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J. Lee, G. Mannaioni, H. Yuan, D. H. Woo, M. B. Gingrich, and S. F. Traynelis
Astrocytic control of synaptic NMDA receptors
J. Physiol.,
June 15, 2007;
581(3):
1057 - 1081.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Bushell
The emergence of proteinase-activated receptor-2 as a novel target for the treatment of inflammation-related CNS disorders
J. Physiol.,
May 15, 2007;
581(1):
7 - 16.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Chrissobolis and C. G. Sobey
Recent Evidence for an Involvement of Rho-Kinase in Cerebral Vascular Disease
Stroke,
August 1, 2006;
37(8):
2174 - 2180.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|